Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
… study has several limitations as of the nature of retrospective design; our data suggest that
gefitinib and erlotinib … , although erlotinib appears to have higher toxicity than gefitinib at each …
gefitinib and erlotinib … , although erlotinib appears to have higher toxicity than gefitinib at each …
[HTML][HTML] Pharmacogenetic analysis of BR. 21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
G Liu, D Cheng, K Ding, A Le Maitre, N Liu… - Journal of Thoracic …, 2012 - Elsevier
… from the cell; ABCG2 polymorphisms have been associated with both gefitinib and erlotinib
… The strengths of this study include (i) the use of data from a randomized clinical trial that …
… The strengths of this study include (i) the use of data from a randomized clinical trial that …
Phase II clinical trial of chemotherapy-naive patients≥ 70 years of age treated with erlotinib for advanced non–small-cell lung cancer
DM Jackman, BY Yeap, NI Lindeman… - Journal of Clinical …, 2007 - ascopubs.org
… When it was discovered that EGFR mutations were associated with sensitivity to gefitinib
and erlotinib 10-12 and that KRAS mutations were associated with resistance to these agents, …
and erlotinib 10-12 and that KRAS mutations were associated with resistance to these agents, …
[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - … Cancer Research, 2021 - ncbi.nlm.nih.gov
… Several randomized controlled trials have suggested that adjuvant epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with prolonged disease-…
receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with prolonged disease-…
… (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
… to gefitinib and erlotinib. However, little is known about how the efficacy and safety profile of
erlotinib … We have performed a prospective, randomized phase III study comparing erlotinib …
erlotinib … We have performed a prospective, randomized phase III study comparing erlotinib …
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
X Li, S Liu, H Gu, D Wang - Journal of cancer research and clinical …, 2012 - Springer
… criteria: (1) randomized as well as non-randomized phase II or III prospective clinical trials
published before August 2011; (2) monotherapy arm with gefitinib or erlotinib; (3) MST could …
published before August 2011; (2) monotherapy arm with gefitinib or erlotinib; (3) MST could …
[HTML][HTML] Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
… treatment with adjuvant erlotinib or gefitinib. Our … a randomized clinical trial, and our
conclusions constitute a lower level of evidence than would be provided by a randomized clinical trial…
conclusions constitute a lower level of evidence than would be provided by a randomized clinical trial…
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR …
… Two studies reported on symptom and QOL effects of … In a nonrandomized study of 57
patients receiving erlotinib as … phase II randomized study of 216 patients treated with gefitinib, 9 …
patients receiving erlotinib as … phase II randomized study of 216 patients treated with gefitinib, 9 …
… placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
… steering committee, after which the clinical study report was produced by AstraZeneca …
Gefitinib (nine in the gefitinib group and 14 in the placebo group), erlotinib (16 in the gefitinib …
Gefitinib (nine in the gefitinib group and 14 in the placebo group), erlotinib (16 in the gefitinib …
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
R Garcia-Campelo, O Arrieta, B Massuti… - Lung Cancer, 2020 - Elsevier
… inhibitors (TKIs), erlotinib and gefitinib, the second-generation … EGFR TKIs are being
evaluated in multiple clinical trials. … erlotinib treated EGFR mutant patients [15,19]. In the present …
evaluated in multiple clinical trials. … erlotinib treated EGFR mutant patients [15,19]. In the present …